Use of azacitidine for myelodysplastic syndromes: controversial issues and practical recommendations

Azacitidine is recommended for patients with higher-risk myelodysplastic syndromes (MDS) who are not eligible for intensive therapy or for patients with lower-risk MDS who have thrombocytopenia or neutropenia or have anemia that is unresponsive to other therapies. However, standard treatment with az...

Deskribapen osoa

Gorde:
Xehetasun bibliografikoak
Egile Nagusiak: Kim, Yoo-Jin, Jang, Jun Ho, Kwak, Jae-Yong, Lee, Je-Hwan, Kim, Hyeoung-Joon
Formatua: Artigo
Hizkuntza:Inglês
Argitaratua: Korean Society of Hematology; Korean Society of Blood and Marrow Transplantation; Korean Society of Pediatric Hematology-Oncology; Korean Society on Thrombosis and Hemostasis 2013
Gaiak:
Review Article
Sarrera elektronikoa:https://ncbi.nlm.nih.gov/pmc/articles/PMC3698413/
https://ncbi.nlm.nih.gov/pubmed/23826577
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.5045/br.2013.48.2.87
Etiketak: Etiketa erantsi
Etiketarik gabe, Izan zaitez lehena erregistro honi etiketa jartzen!

Antzeko izenburuak